Saccharomyces cerevisiae CNCM I-3856

Saccharomyces cerevisiae CNCM I-3856 is a probiotic yeast strain that modulates gut-brain axis signaling through tryptophan metabolism and serotonin regulation. This specific strain demonstrates clinically proven efficacy in reducing IBS symptoms across all subtypes, with particular benefits for abdominal pain and stool consistency.

Origin & History

Saccharomyces cerevisiae CNCM I-3856 is a proprietary probiotic yeast strain registered in the French National Collection of Cultures of Microorganisms, originally derived from baker's yeast. It is characterized through advanced genetic and phenotypic methods including 26S DNA sequencing and genome analysis, and is produced as either live or inactivated whole yeast cells.

Historical & Cultural Context

No traditional or historical medicinal use is documented for this specific CNCM I-3856 strain. As a proprietary modern probiotic strain developed through scientific methods, it lacks traditional medicine context.

Health Benefits

• Reduces abdominal pain and bloating in IBS-C patients - supported by meta-analysis of 2 RCTs (n=579) showing 12.3% reduction in symptoms (PMID: 28127207)
• Improves stool consistency across IBS subtypes - RCT showed significant improvement in IBS-D (p<0.001), IBS-C, and IBS-M patients (PMID: 31807856)
• Alleviates constipation-predominant IBS symptoms - subgroup analysis of 180 IBS-C patients showed significant benefit for pain, bloating, and composite symptoms (PMID: 27403301)
• Reduces intestinal inflammation and permeability - animal studies demonstrate decreased neutrophil recruitment and enhanced barrier function (PMID: 39243351)
• May support vaginal microbiome recovery - preliminary RCT evidence suggests potential benefits (PMID: 32722250)

How It Works

This probiotic yeast modulates the gut-brain axis by regulating tryptophan metabolism and enhancing local serotonin production in the intestinal mucosa. It strengthens intestinal barrier function through increased tight junction protein expression and reduces visceral hypersensitivity by modulating afferent nerve signaling. The strain also produces bioactive metabolites that influence enteric nervous system function and normalize gut motility patterns.

Scientific Research

Clinical evidence includes a large RCT (n=379) showing benefits specifically in IBS-C subgroups (PMID: 27403301), and a meta-analysis of two RCTs (n=579) demonstrating 12.3% reduction in abdominal pain/discomfort (PMID: 28127207). Additional trials confirmed efficacy at 2 billion CFU twice daily for improving stool consistency across IBS subtypes (PMID: 31807856).

Clinical Summary

A meta-analysis of 2 randomized controlled trials (n=579) demonstrated a 12.3% reduction in abdominal pain and bloating in IBS-C patients. Additional RCT evidence shows significant improvements in stool consistency across IBS-D (p<0.001), IBS-C, and IBS-M subtypes. The clinical evidence is moderate quality, with studies focusing primarily on functional gastrointestinal disorders. Most trials used dosages of 5-10 billion CFU daily for 4-8 week intervention periods.

Nutritional Profile

Saccharomyces cerevisiae CNCM I-3856 is a probiotic yeast strain administered primarily for its bioactive and functional properties rather than macronutrient contribution. As a yeast-based organism, its nutritional composition per typical therapeutic dose (500mg or ~10 billion CFU) includes: Protein: approximately 40-50% of dry cell weight, predominantly intracellular proteins and cell wall mannoproteins (not bioavailable in intact live form); Beta-glucans: 25-35% of cell wall dry weight as (1,3)/(1,6)-beta-D-glucans, which contribute to immunomodulatory effects; Mannan-oligosaccharides (MOS): approximately 20-30% of cell wall, supporting gut microbiota modulation; B-vitamins: naturally contains thiamine (B1), riboflavin (B2), niacin (B3), pantothenic acid (B5), pyridoxine (B6), and folate (B9) in trace amounts per dose — insufficient to meet RDA at standard probiotic dosing; Minerals: contains intracellular selenium (as selenomethionine, strain-dependent), zinc, chromium, and iron in trace quantities; Ergosterol (provitamin D2 precursor): present in cell membrane, minimal conversion at standard dosing; Trehalose: intracellular disaccharide serving as cryoprotectant, minimal systemic contribution; Bioavailability note: As a live probiotic organism, macronutrients within intact cells are largely not bioavailable to the host; biological effects are mediated through cell wall components (beta-glucans, mannoproteins), metabolic byproducts (short-chain fatty acids, CO2), and host immune modulation rather than direct nutritional delivery. The strain is typically delivered in lyophilized capsule form at 500mg/day in clinical studies.

Preparation & Dosage

Clinically studied doses include 1000 mg/day of whole yeast powder for 12 weeks, or 2 billion CFU twice daily (total 4 billion CFU/day) for 8 weeks. Both live and inactivated forms have been studied, with live cells showing superior effects in preclinical models. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Lactobacillus acidophilus, Bifidobacterium lactis, Psyllium husk, L-glutamine, Peppermint oil

Safety & Interactions

Saccharomyces cerevisiae CNCM I-3856 is generally well-tolerated with minimal reported side effects in clinical trials. Mild gastrointestinal symptoms like initial bloating may occur during the first few days of supplementation. Immunocompromised individuals should exercise caution as fungemia risk exists, though rare with this specific strain. No significant drug interactions have been reported, but antifungal medications may reduce probiotic efficacy.